Project Grant R01AI193019
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $747K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The Project Grant award for "TARGETED DEGRADATION OF MYCOBACTERIAL PKNG FOR HOST CONTROL OF TUBERCULOSIS" was provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $254,250.00. The award supports research to exploit the macrophage's ubiquitin-proteasome system to degrade the protein kinase G (PknG) enzyme secreted by Mycobacterium tuberculosis (MTB) within macrophages. This approach aims to...
- This Project Grant award of $2,944,529 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand resistance and tolerance to the tuberculosis (TB) drugs pretomanid (PA) and delamanid (DLM) in Mycobacterium tuberculosis (MTB). The goal is to apply innovative genome-wide screens to identify the MTB genes that determine PA/DLM potency, analyze the key resistance determinant...
- This federal Project Grant award, totaling $404,108, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to identify the key genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) to form antibiotic persister cells, which can survive prolonged exposure to lethal antibiotics. The research aims to apply genetic and proteomic approaches to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- This $227,096 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Berkeley to investigate nutrient acquisition strategies utilized by the tuberculosis pathogen Mycobacterium tuberculosis (MTB) during infection of human macrophages. The researchers have developed a novel genetic screening technique called Random Barcode Transposon Site Sequencing (RB-TnSeq) to...
- This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research at Yale University to develop an in vitro culture system that can be used to screen for small molecule inhibitors of drug-tolerant Mycobacterium tuberculosis (MTB) bacteria. The key objectives are to: 1) identify the subcellular environment and carbon source associated with drug-tolerant MTB, and 2) design in vitro...
- This federal Project Grant award of $819,998.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), to The Regents of the University of California, San Francisco. The purpose of the award is to conduct research to understand how Mycobacterium tuberculosis (M. tuberculosis) infection triggers host cell death mechanisms, with the goal of identifying new therapeutic targets to augment protective...
- This Project Grant award of $423,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine the potential of phenylalanine (Phe) biosynthesis as a novel drug target for treating tuberculosis caused by Mycobacterium tuberculosis (MTB). The award will enable the development of MTB strains that conditionally express enzymes in the Phe biosynthesis pathway, which will be used to...
- This Project Grant award of $3,145,850.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award supports research at The Johns Hopkins University to investigate macrophage senescence as a driver of granuloma failure and necrosis in pulmonary tuberculosis (TB) and TB/HIV coinfection. Key objectives include understanding the role of stress-induced senescence in myeloid...
- This Project Grant award of $265,650 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel medicinal chemistry strategies to overcome multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). The research aims to establish the structure-activity relationship and mechanism of action of modified rifabutin analogs that demonstrate enhanced potency against...